

Gisele W B Colleoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5814891/publications.pdf>

Version: 2024-02-01

86
papers

2,252
citations

304368

22
h-index

223531

46
g-index

87
all docs

87
docs citations

87
times ranked

3481
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunosenescence and Cancer. <i>Healthy Ageing and Longevity</i> , 2022, , 165-176.	0.2	0
2	May critical molecular cross-talk between indoleamine 2,3-dioxygenase (IDO) and arginase during human aging be targets for immunosenescence control?. <i>Immunity and Ageing</i> , 2021, 18, 33.	1.8	4
3	Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2019, 519, 597-604.	1.0	15
4	Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism. <i>Scientific Reports</i> , 2019, 9, 1056.	1.6	28
5	Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 269-282.	2.0	19
6	Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines. <i>Current Molecular Medicine</i> , 2019, 19, 112-119.	0.6	1
7	microRNA and Severity of Sickle Cell Anemia. <i>Blood</i> , 2018, 132, 3647-3647.	0.6	1
8	International, evidence-based consensus diagnostic criteria for HHV-8â€“negative/idiopathic multicentric Castleman disease. <i>Blood</i> , 2017, 129, 1646-1657.	0.6	381
9	Plasma cell leukemia with t(11;14)(q13;q32) simulating lymphoplasmacytic lymphoma â€“ a diagnostic challenge solved by flow cytometry. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 66-69.	0.7	7
10	Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients. <i>Cancer Letters</i> , 2017, 403, 206-215.	3.2	31
11	Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 195-212.	2.0	34
12	Observational study of multiple myeloma in Latin America. <i>Annals of Hematology</i> , 2017, 96, 65-72.	0.8	29
13	Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 114698-114709.	0.8	14
14	TP53 Regulated Inhibitor of Apoptosis 1 (TRIAP1) stable silencing increases late apoptosis by upregulation of caspase 9 and APAF1 in RPMI8226 multiple myeloma cell line. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 1105-1110.	1.8	22
15	Association of VEGFA-2578 C>A polymorphism with clinicopathological aspects and outcome in follicular lymphoma patients. <i>Blood Cancer Journal</i> , 2016, 6, e464-e464.	2.8	7
16	Multiple Myeloma Cancer Stem Cells: Immunophenotypic and Functional Characterization, Gene Expression Profiling and Therapeutic Targets. <i>Blood</i> , 2016, 128, 4434-4434.	0.6	1
17	Heat Shock Protein 70 Inhibitor, Alone or in Combination with Bortezomib, Prevented Plasmacytoma Development in Immunodeficient Mice Transplanted with Myeloma Cell Lines. <i>Blood</i> , 2016, 128, 5658-5658.	0.6	1
18	Angiomirs expression profiling in diffuse large B-Cell lymphoma. <i>Oncotarget</i> , 2016, 7, 4806-4816.	0.8	24

#	ARTICLE	IF	CITATIONS
19	In Vitro JAK1/2 Inhibition, in Association with Bortezomib and Lenalidomide, Is Comparable with Bortezomib, Lenalidomide and Dexametasone: An Alternative for Multiple Myeloma Patients with JAK2 overexpression?. Blood, 2016, 128, 5663-5663.	0.6	0
20	Prognosis of Patients with Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (PTLD-CNS) Treated with Immunossuppression Reduction, Intrathecal Chemotherapy and Whole-Brain Radiotherapy: An Analysis of 23 Patients in a Brazilian Cohort. Blood, 2015, 126, 3913-3913.	0.6	3
21	Clinical Outcome of 96 Post-Transplant Lymphoproliferative Disease Patients in a Renal Transplant Cohort. Blood, 2015, 126, 5054-5054.	0.6	0
22	FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells. Cancer Immunology, Immunotherapy, 2014, 63, 1189-1197.	2.0	65
23	Is there any relationship between gene expression of tumor antigens and CD4+T cells in multiple myeloma?. Immunotherapy, 2014, 6, 569-575.	1.0	1
24	Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1. Leukemia and Lymphoma, 2014, 55, 1176-1180.	0.6	1
25	A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly. Oncotarget, 2014, 5, 11813-11826.	0.8	32
26	VEGF 2578 c>a, a Functional Angiogenic Polymorphism, Is Associated with Aggressiveness and Clinical Outcome of Follicular Lymphoma. Blood, 2014, 124, 3022-3022.	0.6	0
27	MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. Cancer Immunology, Immunotherapy, 2013, 62, 191-195.	2.0	23
28	Understanding myeloma cancer stem cells. Immunotherapy, 2013, 5, 1291-1294.	1.0	1
29	Serum free light chains and post-transplant lymphoproliferative disorder in patients with renal transplant. Leukemia and Lymphoma, 2013, 54, 2177-2180.	0.6	6
30	Multiple Myeloma Profile In Latin America: Clinical and Epidemiological Observational Study. Blood, 2013, 122, 5327-5327.	0.6	1
31	Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy. Clinical and Developmental Immunology, 2012, 2012, 1-7.	3.3	30
32	The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma. Clinical and Developmental Immunology, 2012, 2012, 1-4.	3.3	46
33	Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients. Cancer Immunology, Immunotherapy, 2012, 61, 2207-2214.	2.0	15
34	An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients. BMC Cancer, 2011, 11, 416.	1.1	12
35	Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines. PLoS ONE, 2011, 6, e27707.	1.1	21
36	Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients. Clinics, 2011, 66, 1855-9.	0.6	8

#	ARTICLE	IF	CITATIONS
37	Comparative Expression of a Set of Genes to an Internal Housekeeping Control in CDNA Amplified and not Amplified by PolyAPCR in Non-Hodgkin's Lymphoma Samples Obtained From Fine-Needle Aspiration Cytology. <i>Diagnostic Molecular Pathology</i> , 2010, 19, 40-44.	2.1	3
38	Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy. <i>Leukemia and Lymphoma</i> , 2010, 51, 1543-1549.	0.6	6
39	Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma. <i>Experimental Hematology</i> , 2009, 37, 446-449.	0.2	13
40	TGF β 2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. <i>International Journal of Cancer</i> , 2009, 125, 1985-1991.	2.3	48
41	SAGE analysis highlights the importance of p53, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis. <i>Cancer Letters</i> , 2009, 278, 41-48.	3.2	51
42	Proangiogenic cytokines produced by non-Hodgkin lymphoma tumor cells induce angiogenesis in infiltrated bone marrow samples. <i>Leukemia and Lymphoma</i> , 2009, 50, 1381-1383.	0.6	4
43	Expression of eight genes of nuclear factor-kappa B pathway in multiple myeloma using bone marrow aspirates obtained at diagnosis. <i>Histology and Histopathology</i> , 2009, 24, 991-7.	0.5	13
44	Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 257-264.	0.6	13
45	Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. <i>Haematologica</i> , 2008, 93, 791-792.	1.7	34
46	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098.	0.6	173
47	Poor Survival Predicted by MDM2 Oncoprotein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Wild-Type TP53 Gene. <i>Blood</i> , 2008, 112, 5269-5269.	0.6	2
48	Expression of Cancer-Testis Antigens in Non-Hodgkin's Lymphomas. <i>Blood</i> , 2008, 112, 5281-5281.	0.6	0
49	Frequency and Prognostic Relevance of Cancer Testis Antigen 45 Expression in Multiple Myeloma. <i>Blood</i> , 2008, 112, 5134-5134.	0.6	0
50	TGF β 2 Methylation Assessed by Quantitative-MSP in Multiple Myeloma Patients: An Independent Prognostic Marker. <i>Blood</i> , 2008, 112, 4475-4475.	0.6	21
51	Identification of New Upregulated Genes with Possible Relevance for Multiple Myeloma Tumorigenesis. <i>Blood</i> , 2008, 112, 2707-2707.	0.6	0
52	Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. <i>Cancer Immunity</i> , 2008, 8, 2.	3.2	76
53	Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients?. <i>Leukemia and Lymphoma</i> , 2007, 48, 526-530.	0.6	6
54	Tratamento de primeira linha no Mieloma Múltiplo. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2007, 29, .	0.7	0

#	ARTICLE	IF	CITATIONS
55	Essential thrombocythemia after treatment of non-Hodgkin's lymphoma. <i>Leukemia Research</i> , 2007, 31, 1593-1595.	0.4	3
56	Analysis of polymorphism at site -174 G/C of interleukin-6 promoter region in multiple myeloma. <i>Brazilian Journal of Medical and Biological Research</i> , 2007, 40, 265-267.	0.7	23
57	Psychosocial adaptation and quality of life among Brazilian patients with different hematological malignancies. <i>Journal of Psychosomatic Research</i> , 2006, 60, 505-511.	1.2	54
58	Cutaneous T-cell lymphoma with HTLV-I infection: clinical overlap with adult T-cell leukemia/lymphoma. <i>International Journal of Dermatology</i> , 2006, 45, 447-449.	0.5	15
59	Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression. <i>Brazilian Journal of Medical and Biological Research</i> , 2005, 38, 1609-1613.	0.7	3
60	p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma. <i>Cancer Letters</i> , 2005, 222, 247-254.	3.2	26
61	Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: A nested case-control study in a renal transplant cohort. <i>Leukemia and Lymphoma</i> , 2005, 46, 533-539.	0.6	32
62	Validation of International Staging System (ISS) for Multiple Myeloma: A Retrospective Analysis of 487 Patients at 8 Brazilian Centers. <i>Blood</i> , 2005, 106, 5069-5069.	0.6	0
63	Bilateral Central Retinal Vein Occlusion Associated with Multiple Myeloma. <i>Ophthalmologica</i> , 2004, 218, 283-287.	1.0	22
64	Correlation Between Histological Subtype and Type of bcl-2/IgH Rearrangement in Follicular Lymphomas. <i>Leukemia and Lymphoma</i> , 2004, 45, 331-338.	0.6	2
65	Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma. <i>Acta Oncologica</i> , 2004, 43, 215-216.	0.8	4
66	Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. <i>European Journal of Haematology</i> , 2004, 73, 311-317.	1.1	31
67	Detection and Possible Prognostic Relevance of p53 Gene Mutations in Diffuse Large B-cell Lymphoma. An Analysis of 51 Cases and Review of the Literature. <i>Leukemia and Lymphoma</i> , 2004, 45, 2071-2078.	0.6	37
68	Possible Influence of Clinical Stage and Type of Treatment in the Persistence of Residual Circulating t(14;18)-Positive Cells in Follicular Lymphoma Patients. <i>Leukemia and Lymphoma</i> , 2004, 45, 539-545.	0.6	6
69	Molecular analysis of gastric washings in the diagnosis and monitoring of gastric lymphomas. <i>Human Pathology</i> , 2004, 35, 582-586.	1.1	0
70	Quantification of Epstein-Barr viral load and determination of a cut-off value to predict the risk of post-transplant lymphoproliferative disease in a renal transplant cohort. <i>Haematologica</i> , 2004, 89, 366-8.	1.7	10
71	Can thalidomide be effective to treat plasma cell leptomeningeal infiltration?. <i>European Journal of Haematology</i> , 2003, 70, 198-199.	1.1	21
72	Primary Breast Lymphoma: An Uncommon but Curable Disease. <i>Leukemia and Lymphoma</i> , 2003, 44, 149-151.	0.6	20

#	ARTICLE	IF	CITATIONS
73	Advances in the Treatment of Multiple Myeloma: The Role of Thalidomide. <i>Leukemia and Lymphoma</i> , 2003, 44, 291-298.	0.6	9
74	Letter to the Editor. <i>Leukemia and Lymphoma</i> , 2003, 44, 1837-1839.	0.6	6
75	2-Chloro-deoxyadenosine Induces Durable Complete Remission in Castleman's Disease but may Accelerate its Transformation to Non-Hodgkin's Lymphoma. <i>Acta Oncol³gica</i> , 2003, 42, 784-787.	0.8	9
76	Reciprocal Cdc25A and p27 Expression in B-Cell Non-Hodgkin Lymphomas. <i>Diagnostic Molecular Pathology</i> , 2003, 12, 128-132.	2.1	8
77	Impact of Highly Active Antiretroviral Therapy in the Treatment of HIV ⁺ Infected Patients with Systemic Non-Hodgkin's Lymphoma. <i>Acta Oncol³gica</i> , 2002, 41, 192-196.	0.8	12
78	Expression of SSX genes in the neoplastic cells of Hodgkin's lymphoma. <i>Human Pathology</i> , 2002, 33, 496-502.	1.1	16
79	Fusion of the ALK Gene to the Clathrin Heavy Chain Gene, CLTC, in Inflammatory Myofibroblastic Tumor. <i>American Journal of Pathology</i> , 2001, 159, 411-415.	1.9	335
80	Comparison of a Multiplex Reverse Transcriptase ⁺ Polymerase Chain Reaction for BCR-ABL to Fluorescence In Situ Hybridization, Southern Blotting, and Conventional Cytogenetics in the Monitoring of Patients With Ph1-Positive Leukemias. <i>Diagnostic Molecular Pathology</i> , 2000, 9, 203-209.	2.1	10
81	AT1C-ALK: A Novel Variant ALK Gene Fusion in Anaplastic Large Cell Lymphoma Resulting from the Recurrent Cryptic Chromosomal Inversion, inv(2)(p23q35). <i>American Journal of Pathology</i> , 2000, 156, 781-789.	1.9	168
82	Post-Transplant Lymphoproliferative Disorders (PTLD) after Renal Transplantation: Management and Evolution of Seven Cases Among 1002 Renal Transplants in Sao Paulo, Brazil. <i>Leukemia and Lymphoma</i> , 2000, 39, 145-150.	0.6	13
83	Clinical management of six cases of low-risk primary tonsillar non-Hodgkin's lymphoma. <i>Sao Paulo Medical Journal</i> , 1999, 117, 215-217.	0.4	0
84	Granulocytic sarcoma presented as a reactivation of chronic myeloid leukemia after allogenic marrow transplantation. <i>Sao Paulo Medical Journal</i> , 1998, 116, 1689-1691.	0.4	2
85	Relationship Between the Type of BCR-ABL Rearrangement and Bone Marrow Histopathological Features in Chronic Myeloid Leukemia. <i>Acta Oncol³gica</i> , 1997, 36, 313-315.	0.8	0
86	BCR-ABL Rearrangement in Adult T-cell Acute Lymphoblastic Leukemia. <i>American Journal of Hematology</i> , 1996, 53, 277-278.	2.0	8